MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com
Clinical Trials
Related News

Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration

Completed
Conditions
Macular Degeneration
Interventions
First Posted Date
2007-04-16
Last Posted Date
2012-12-11
Lead Sponsor
Pfizer
Target Recruit Count
501
Registration Number
NCT00460408
Locations
🇸🇪

Pfizer Investigational Site, Västerås, Sweden

Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule

Phase 3
Completed
Conditions
Encephalitis, Tick-Borne
First Posted Date
2007-04-16
Last Posted Date
2023-04-19
Lead Sponsor
Pfizer
Target Recruit Count
330
Registration Number
NCT00460486
Locations
🇵🇱

Niepubliczny ZOZ "VITA", Olsztyn, Poland

🇵🇱

Centrum Badan Farmakologii Klinicznej monipol, Krakow, Poland

🇵🇱

Niepubliczny ZOZ "Atarax" s.c., Olsztyn, Poland

and more 1 locations

Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Device: Enbrel 50 mg Prefilled Syringe
Device: Enbrel 50 mg Autoinjector
First Posted Date
2007-04-12
Last Posted Date
2013-03-28
Lead Sponsor
Pfizer
Target Recruit Count
640
Registration Number
NCT00459706

A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

Phase 3
Completed
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
Drug: placebo
First Posted Date
2007-04-06
Last Posted Date
2013-10-29
Lead Sponsor
Pfizer
Target Recruit Count
960
Registration Number
NCT00457392
Locations
🇬🇧

Pfizer Investigational Site, Yeovil, Somerset, United Kingdom

A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)

Phase 2
Withdrawn
Conditions
Diabetic Retinopathy
Diabetes Mellitus
First Posted Date
2007-04-06
Last Posted Date
2015-05-04
Lead Sponsor
Pfizer
Registration Number
NCT00457470

Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer

Phase 3
Completed
Conditions
Metastatic Colorectal Cancer
Interventions
Drug: placebo
First Posted Date
2007-04-06
Last Posted Date
2015-03-30
Lead Sponsor
Pfizer
Target Recruit Count
768
Registration Number
NCT00457691
Locations
🇬🇧

Pfizer Investigational Site, Manchester, United Kingdom

A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)

Phase 1
Completed
Conditions
Gastrointestinal Stromal Tumors
Interventions
First Posted Date
2007-04-06
Last Posted Date
2009-11-13
Lead Sponsor
Pfizer
Target Recruit Count
36
Registration Number
NCT00457743
Locations
🇯🇵

Pfizer Investigational Site, Chuo-ku, Tokyo, Japan

Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.

Phase 2
Completed
Conditions
Prostatic Hyperplasia
Interventions
First Posted Date
2007-04-06
Last Posted Date
2018-12-19
Lead Sponsor
Pfizer
Target Recruit Count
609
Registration Number
NCT00457457
Locations
🇬🇧

Pfizer Investigational Site, Bristol, United Kingdom

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

First Posted Date
2007-04-02
Last Posted Date
2012-04-04
Lead Sponsor
Pfizer
Target Recruit Count
102
Registration Number
NCT00454649
Locations
🇪🇸

Pfizer Investigational Site, Madrid, Spain

A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease

Phase 1
Completed
Conditions
Alzheimer's Disease
Interventions
Biological: PF-04360365
Drug: Placebo
First Posted Date
2007-04-02
Last Posted Date
2009-10-14
Lead Sponsor
Pfizer
Target Recruit Count
37
Registration Number
NCT00455000
Locations
🇬🇧

Pfizer Investigational Site, Southampton, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy